What is the recommended dosing of guaifenesin (Mucinex) for adults and children, and how should the dose be adjusted in renal impairment or pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mucinex (Guaifenesin) Dosing

For adults and children 12 years and older, take 1-2 extended-release tablets (600 mg each) every 12 hours, not exceeding 4 tablets in 24 hours; Mucinex is not approved for children under 12 years of age. 1

Standard Adult Dosing

  • Adults and adolescents ≥12 years: 600-1200 mg (1-2 extended-release tablets) every 12 hours 1
  • Maximum daily dose: 2400 mg (4 extended-release tablets) in 24 hours 1
  • Administration: Take with a full glass of water; do not crush, chew, or break the extended-release tablet 1
  • Food considerations: Can be administered without regard to timing of meals 1

Pediatric Dosing

  • Children <12 years: Not approved for use with the 600 mg extended-release formulation 1
  • For immediate-release formulations in younger children, age-based dosing of 100-400 mg has been studied, though specific recommendations should follow product labeling 2

Renal Impairment

Guaifenesin should be used with caution in patients with renal impairment, as the drug and its metabolites are renally cleared. 3

  • No specific dose adjustment guidelines are established in the FDA labeling 1
  • Transplant literature suggests careful monitoring in patients with reduced renal function due to potential accumulation 3
  • Consider reduced dosing frequency or lower doses in severe renal impairment, though formal recommendations are lacking 3

Pregnancy Considerations

  • Pregnancy category: Not formally classified in current FDA labeling 1
  • Guaifenesin has been used in pregnancy, though data are limited 3
  • General principle: Use only if benefits outweigh potential risks, as with most medications in pregnancy
  • No specific teratogenic concerns have been documented in available literature

Important Clinical Considerations

Pharmacokinetics

  • Half-life: Short elimination half-life necessitates frequent dosing with immediate-release formulations 4
  • Extended-release formulation: Provides 12-hour therapeutic effect, improving convenience and adherence 4
  • Bioequivalence: 1200 mg extended-release every 12 hours is bioequivalent to 400 mg immediate-release every 4 hours 4

Safety Profile

  • Well-tolerated: Favorable safety profile in adult and pediatric populations 5, 6
  • Common adverse effects: Primarily gastrointestinal (nausea, vomiting), nervous system symptoms (headache), all typically mild in severity 5
  • Serious adverse events: Rare; no deaths or serious adverse events reported in post-marketing surveillance 5

Special Populations

  • Transplant recipients: Can be used but requires caution in kidney and lung transplant patients with renal impairment 3
  • Hepatic impairment: No specific precautions mentioned in available evidence, though patients with liver transplant should exercise greater caution 3

References

Related Questions

What are the recommended dosing guidelines for Mucinex (guaifenesin) in adults, adolescents, children aged 4‑11 years, and in elderly or patients with renal or hepatic impairment?
What is the recommended dose for Mucinex (guaifenesin)?
What is the recommended dosing of Mucinex (guaifenesin) for adults, children ≥12 years, children 4–11 years, and what adjustments are needed for renal impairment, pregnancy, or nursing?
What is the recommended dosage frequency of guaifenesin for a patient with chest congestion?
Can I give 2.5 ml of guaifenesin to an 11-month-old child?
In a patient with well‑controlled diabetes and hypertension who presents with burning pain, numbness, paresthesias, gait instability, and autonomic dysfunction while taking amiodarone, is his neuropathy more likely due to amiodarone‑induced neurotoxicity rather than chronic inflammatory demyelinating polyneuropathy (CIDP)?
What is the recommended evaluation and treatment for ulcer-like dyspepsia?
What factors most often predict poor prognosis in somatic symptom disorder?
Is herpes simplex virus type 1 (HSV‑1) or enterovirus the most common cause of viral encephalitis?
In a patient on amiodarone who has distal burning pain, numbness, paresthesias, and gait instability, but also shows true spasticity, a positive Babinski sign, an upper‑motor‑neuron pattern, and bowel/bladder dysfunction, can amiodarone‑induced peripheral neuropathy explain these central signs, or what further evaluation is needed?
For an adult with chronic heart failure and iron deficiency (ferritin <100 µg/L or 100‑300 µg/L with transferrin saturation <20 %), is intravenous iron infusion preferred over oral iron supplementation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question